Council, Segal honored for development efforts
The Population Council, a New York City-based reproductive health research organization, and Sheldon Segal, PhD, distinguished scientist at the council, have been scheduled to receive the 2008 Prix Galien USA Pro Bono Humanum Award for their role in developing implantable hormone delivery systems.
At press time, the award was scheduled to be presented Sept. 24, 2008, at the American Museum of Natural History in New York City. The Prix Galien USA Award recognizes the technical, scientific, and clinical research skills necessary to develop innovative medicines that improve the human condition. It is considered the industry's highest accolade for pharmaceutical research and development.
Segal was singled out for his direction of the research and development of Norplant, the first contraceptive implant on the market. Currently, 8 million women worldwide use contraceptive implants such as Norplant, Implanon, and Jadelle.
"I am delighted that the distinguished Prix Galien selection committee has selected the Population Council and Dr. Segal for this honor," said Peter Donaldson, Population Council president, in the announcement of the award.
The Population Council estimates more than 100 million women around the world have used a form, developed by the Population Council, of long-term reversible contraception.
The Population Council, a New York City-based reproductive health research organization, and Sheldon Segal, PhD, distinguished scientist at the council, have been scheduled to receive the 2008 Prix Galien USA Pro Bono Humanum Award for their role in developing implantable hormone delivery systems.You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content